Literature DB >> 19171142

Galectin-1 is a novel functional receptor for tissue plasminogen activator in pancreatic cancer.

Oriol Roda1, Elena Ortiz-Zapater, Neus Martínez-Bosch, Ricardo Gutiérrez-Gallego, Miquel Vila-Perelló, Coral Ampurdanés, Hans-Joachim Gabius, Sabine André, David Andreu, Francisco X Real, Pilar Navarro.   

Abstract

BACKGROUND & AIMS: Tissue plasminogen activator (tPA) exerts many different functions in addition to its role in fibrinolysis. In pancreatic ductal adenocarcinoma (PDA), tPA is overexpressed and plays an important role in proliferation, invasion, and angiogenesis. tPA interaction with cell membrane receptors has been related to increased proteolytic activity and to signal transduction through nonenzymatic mechanisms. The aim was to analyze the role of galectin-1 (Gal-1), an endogenous lectin that also is overexpressed in PDA, as a new functional receptor for tPA.
METHODS: Gal-1/tPA interaction was analyzed using surface plasmon resonance and pull-down assays. Pancreatic cells and tumors were used to study Gal-1 expression and localization by Western blot and immunostaining. Down-regulation of Gal-1 by small interference RNA was used to analyze the involvement of Gal-1/tPA interaction in extracellular signal-regulated kinase 1/2 activation, cell proliferation, and invasion in pancreatic and fibroblastic cells.
RESULTS: Gal-1/tPA interaction is direct, specific, and of high affinity. Gal-1 moderately increases the catalytic activity of tPA. High Gal-1 levels were detected in PDA cells in culture, where it concentrates at the migration front, and in tissues, where it is expressed in epithelial cells and in the stroma. Down-regulation of Gal-1 abolished the effects of tPA on extracellular signal-regulated kinase 1/2 activation, cell proliferation, and invasion, both in pancreatic and in tumor-derived fibroblasts.
CONCLUSIONS: These findings support a new molecular mechanism by which Gal-1 interaction with tPA contributes to PDA progression involving both transformed epithelial cells and tumor fibroblasts.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19171142     DOI: 10.1053/j.gastro.2008.12.039

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  28 in total

Review 1.  Pancreatic ductal adenocarcinoma and transcription factors: role of c-Myc.

Authors:  Anouchka Skoudy; Inmaculada Hernández-Muñoz; Pilar Navarro
Journal:  J Gastrointest Cancer       Date:  2011-06

2.  Binding of Toxoplasma gondii glycosylphosphatidylinositols to galectin-3 is required for their recognition by macrophages.

Authors:  Françoise Debierre-Grockiego; Sebastian Niehus; Bernadette Coddeville; Elisabeth Elass; Françoise Poirier; Ralf Weingart; Richard R Schmidt; Joël Mazurier; Yann Guérardel; Ralph T Schwarz
Journal:  J Biol Chem       Date:  2010-08-20       Impact factor: 5.157

3.  Targeting Galectin-1 in pancreatic cancer: immune surveillance on guard.

Authors:  Neus Martínez-Bosch; Pilar Navarro
Journal:  Oncoimmunology       Date:  2014-08-03       Impact factor: 8.110

Review 4.  The wound healing, chronic fibrosis, and cancer progression triad.

Authors:  Brad Rybinski; Janusz Franco-Barraza; Edna Cukierman
Journal:  Physiol Genomics       Date:  2014-02-11       Impact factor: 3.107

5.  Galectin-1 drives pancreatic carcinogenesis through stroma remodeling and Hedgehog signaling activation.

Authors:  Neus Martínez-Bosch; Maite G Fernández-Barrena; Mireia Moreno; Elena Ortiz-Zapater; Jessica Munné-Collado; Mar Iglesias; Sabine André; Hans-Joachim Gabius; Rosa F Hwang; Françoise Poirier; Carolina Navas; Carmen Guerra; Martin E Fernández-Zapico; Pilar Navarro
Journal:  Cancer Res       Date:  2014-05-08       Impact factor: 12.701

Review 6.  Do galectins play a role in venous thrombosis? a review.

Authors:  Jose A Diaz; Eduardo Ramacciotti; Thomas W Wakefield
Journal:  Thromb Res       Date:  2009-12-02       Impact factor: 3.944

Review 7.  Intrahepatic cholangiocarcinoma progression: prognostic factors and basic mechanisms.

Authors:  Alphonse E Sirica; Catherine I Dumur; Deanna J W Campbell; Jorge A Almenara; Olorunseun O Ogunwobi; Jennifer L Dewitt
Journal:  Clin Gastroenterol Hepatol       Date:  2009-11       Impact factor: 11.382

8.  Gal-1 silenced trophoblast tumor cells (BeWo) show decreased syncytium formation and different miRNA production compared to non-target silenced BeWo cells.

Authors:  Stefan Hutter; Diana M Morales-Prieto; Ulrich Andergassen; Lisa Tschakert; Christina Kuhn; Simone Hofmann; Udo R Markert; Udo Jeschke
Journal:  Cell Adh Migr       Date:  2015-09-29       Impact factor: 3.405

Review 9.  Tissue proteomics in pancreatic cancer study: discovery, emerging technologies, and challenges.

Authors:  Sheng Pan; Teresa A Brentnall; Kimberly Kelly; Ru Chen
Journal:  Proteomics       Date:  2013-01-07       Impact factor: 3.984

10.  Targeting galectin-1 inhibits pancreatic cancer progression by modulating tumor-stroma crosstalk.

Authors:  Carlos A Orozco; Neus Martinez-Bosch; Pedro E Guerrero; Judith Vinaixa; Tomás Dalotto-Moreno; Mar Iglesias; Mireia Moreno; Magdolna Djurec; Françoise Poirier; Hans-Joachim Gabius; Martin E Fernandez-Zapico; Rosa F Hwang; Carmen Guerra; Gabriel A Rabinovich; Pilar Navarro
Journal:  Proc Natl Acad Sci U S A       Date:  2018-04-03       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.